{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:37:32Z","timestamp":1788957452675,"version":"build-2803163510"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40263-021-00804-1","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T06:02:52Z","timestamp":1616220172000},"page":"317-330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6423-1495","authenticated-orcid":false,"given":"Anthony T.","family":"Reder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8390-8545","authenticated-orcid":false,"given":"Diego","family":"Centonze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"Naylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2711-445X","authenticated-orcid":false,"given":"Anjali","family":"Nagpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajani","family":"Rajbhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Altincatal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Berdofe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred W.","family":"Sandrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Smirnakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catrinel","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"de Moor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,20]]},"reference":[{"key":"804_CR1","unstructured":"World Health Organization. Pneumonia of unknown cause: China. 2020. https:\/\/www.who.int\/csr\/don\/05-january-2020-pneumonia-of-unkown-cause-china\/en\/. Accessed 7 Sept 2020."},{"issue":"13","key":"804_CR2","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMe2002387","volume":"382","author":"AS Fauci","year":"2020","unstructured":"Fauci AS, Lane HC, Redfield RR. COVID-19: navigating the uncharted. N Engl J Med. 2020;382(13):1268\u20139.","journal-title":"N Engl J Med."},{"issue":"6","key":"804_CR3","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s10096-020-03874-z","volume":"39","author":"H Ge","year":"2020","unstructured":"Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T, et al. The epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect Dis. 2020;39(6):1011\u20139.","journal-title":"Eur J Clin Microbiol Infect Dis."},{"issue":"10224","key":"804_CR4","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565\u201374.","journal-title":"Lancet"},{"key":"804_CR5","unstructured":"World Health Organization. WHO coronavirus disease (COVID-19) dashboard. 2020. https:\/\/covid19.who.int\/?gclid=EAIaIQobChMIz-i4-f2i7AIVjIFaBR0ZXAxOEAAYASAAEgIiDPD_BwE. Accessed 7 Oct 2020."},{"issue":"2","key":"804_CR6","doi-asserted-by":"publisher","first-page":"e000862","DOI":"10.1136\/jitc-2020-000862","volume":"8","author":"J Wei","year":"2020","unstructured":"Wei J, Zhao J, Han M, Meng F, Zhou J. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity. J Immunother Cancer. 2020;8(2):e000862.","journal-title":"J Immunother Cancer."},{"issue":"6","key":"804_CR7","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1002\/ana.25907","volume":"88","author":"JR Ciotti","year":"2020","unstructured":"Ciotti JR, Grebenciucova E, Moss BP, Newsome SD. Multiple sclerosis disease-modifying therapies in the COVID-19 era. Ann Neurol. 2020;88(6):1062\u20134. https:\/\/doi.org\/10.1002\/ana.25907.","journal-title":"Ann Neurol."},{"key":"804_CR8","doi-asserted-by":"crossref","unstructured":"Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. COVID-19 global rheumatology alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859\u201366.","DOI":"10.1136\/annrheumdis-2020-217871"},{"key":"804_CR9","doi-asserted-by":"publisher","first-page":"102420","DOI":"10.1016\/j.msard.2020.102420","volume":"45","author":"A Castelo-Branco","year":"2020","unstructured":"Castelo-Branco A, Chiesa F, Conte S, Bengtsson C, Lee S, Minton N, et al. Infections in patients with multiple sclerosis: a national cohort study in Sweden. Mult Scler Relat Disord. 2020;45:102420.","journal-title":"Mult Scler Relat Disord."},{"issue":"12","key":"804_CR10","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1177\/0961203313493032","volume":"22","author":"A Danza","year":"2013","unstructured":"Danza A, Ruiz-Irastorza G. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus. 2013;22(12):1286\u201394.","journal-title":"Lupus"},{"issue":"6","key":"804_CR11","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3390\/brainsci10060345","volume":"10","author":"MK Boziki","year":"2020","unstructured":"Boziki MK, Mentis AFA, Shumilina M, Makshakov G, Evdoshenko E, Grigoriadis N. COVID-19 immunopathology and the central nervous system: implication for multiple sclerosis and other autoimmune diseases with associated demyelination. Brain Sci. 2020;10(6):345.","journal-title":"Brain Sci."},{"key":"804_CR12","unstructured":"MS International Federation. Global COVID-19 advice for people with MS. 2020. http:\/\/www.msif.org\/wp-content\/uploads\/2020\/06\/MSIF-Global-advice-on-COVID-19-for-people-with-MS-_-updated17June2020.pdf. Accessed 21 Oct 2020."},{"issue":"Suppl. 1","key":"804_CR13","first-page":"S5","volume":"23","author":"R Bhatia","year":"2020","unstructured":"Bhatia R, Srivastava MVP, Khurana D, Pandit L, Mathew T, Gupta S, et al. Consensus statement on immune modulation in multiple sclerosis and related disorders during the COVID-19 pandemic: expert group on behalf of the Indian Academy of Neurology. Ann Indian Acad Neurol. 2020;23(Suppl. 1):S5-14.","journal-title":"Ann Indian Acad Neurol."},{"key":"804_CR14","unstructured":"Centers for Disease Control and Prevention. If you are immunocompromised, protect yourself from COVID-19. 2020. http:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/immunocompromised.html. Accessed 21 Oct 2020."},{"issue":"17","key":"804_CR15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777\u201388.","journal-title":"Neurology"},{"issue":"4","key":"804_CR16","doi-asserted-by":"publisher","first-page":"e761","DOI":"10.1212\/NXI.0000000000000761","volume":"7","author":"JR Berger","year":"2020","unstructured":"Berger JR, Brandstadter R, Bar-Or A. COVID-19 and MS disease-modifying therapies. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e761.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"5","key":"804_CR17","doi-asserted-by":"publisher","first-page":"e787","DOI":"10.1212\/NXI.0000000000000787","volume":"7","author":"M Fan","year":"2020","unstructured":"Fan M, Qiu W, Bu B, Xu Y, Yang H, Huang D, et al. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e787.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"5","key":"804_CR18","doi-asserted-by":"publisher","first-page":"e835","DOI":"10.1212\/NXI.0000000000000835","volume":"7","author":"E Parrotta","year":"2020","unstructured":"Parrotta E, Kister I, Charvet L, Sammarco C, Saha V, Charlson RE, et al. COVID-19 outcomes in MS: observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e835.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"804_CR19","doi-asserted-by":"crossref","unstructured":"Fernandez-Ruiz R, Masson M, Kim MY, Myers B, Haberman RH, Castillo R, et al. NYU WARCOV Investigators. Leveraging the United States epicenter to provide insights on COVID-19 in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2020;72(12):1971\u201380.","DOI":"10.1002\/art.41450"},{"key":"804_CR20","doi-asserted-by":"publisher","first-page":"102502","DOI":"10.1016\/j.jaut.2020.102502","volume":"112","author":"M Zen","year":"2020","unstructured":"Zen M, Fuzzi E, Astorri D, Saccon F, Padoan R, Ienna L, et al. SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: a cross-sectional study on 916 patients. J Autoimmun. 2020;112:102502.","journal-title":"J Autoimmun."},{"issue":"Suppl. 201","key":"804_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ane.12835","volume":"136","author":"EG Celius","year":"2017","unstructured":"Celius EG. Infections in patients with multiple sclerosis: implications for disease-modifying therapy. Acta Neurol Scand. 2017;136(Suppl. 201):34\u20136.","journal-title":"Acta Neurol Scand."},{"key":"804_CR22","doi-asserted-by":"crossref","unstructured":"Sormani MP. Italian Study Group on COVID-19 infection in multiple sclerosis. An Italian programme for COVID-19 infection in multiple sclerosis. Lancet Neurol. 2020;19(6):481\u20132.","DOI":"10.1016\/S1474-4422(20)30147-2"},{"key":"804_CR23","doi-asserted-by":"publisher","first-page":"102073","DOI":"10.1016\/j.msard.2020.102073","volume":"39","author":"G Giovannoni","year":"2020","unstructured":"Giovannoni G, Hawkes C, Lechner-Scott J, Levy M, Waubant E, Gold J. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord. 2020;39:102073.","journal-title":"Mult Scler Relat Disord."},{"key":"804_CR24","doi-asserted-by":"publisher","first-page":"104791","DOI":"10.1016\/j.antiviral.2020.104791","volume":"178","author":"E Sallard","year":"2020","unstructured":"Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a potential treatment against COVID-19. Antivir Res. 2020;178:104791.","journal-title":"Antivir Res."},{"key":"804_CR25","doi-asserted-by":"publisher","first-page":"102439","DOI":"10.1016\/j.msard.2020.102439","volume":"45","author":"JR Ciotti","year":"2020","unstructured":"Ciotti JR, Valtcheva MV, Cross AH. Effects of MS disease-modifying therapies on responses to vaccinations: a review. Mult Scler Relat Disord. 2020;45:102439.","journal-title":"Mult Scler Relat Disord."},{"key":"804_CR26","doi-asserted-by":"crossref","unstructured":"Louapre C, Collongues N, Stankoff B, Giannesini C, Papeix C, Bensa C, et al. Covisep Investigators. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020;77(9):1\u201310.","DOI":"10.1001\/jamaneurol.2020.2581"},{"key":"804_CR27","doi-asserted-by":"publisher","first-page":"101904","DOI":"10.1016\/j.tmaid.2020.101904","volume":"38","author":"R Tirupathi","year":"2020","unstructured":"Tirupathi R, Muradova V, Shekhar R, Salim SA, Al-Tawfiq JA, Palabindala V. COVID-19 disparity among racial and ethnic minorities in the US: a cross sectional analysis. Travel Med Infect Dis. 2020;38:101904.","journal-title":"Travel Med Infect Dis."},{"issue":"10","key":"804_CR28","doi-asserted-by":"publisher","first-page":"e1003402","DOI":"10.1371\/journal.pmed.1003402","volume":"17","author":"MT Bassett","year":"2020","unstructured":"Bassett MT, Chen JT, Krieger N. Variation in racial\/ethnic disparities in COVID-19 mortality by age in the United States: a cross-sectional study. PLoS Med. 2020;17(10):e1003402.","journal-title":"PLoS Med."},{"key":"804_CR29","unstructured":"Zabalza A, Tagliani P, C\u00e1rdenas-Robledo S, Arrambide G, Otero-Romero S, Carbonell-Mirabent P, et al. COVID-19 in MS patients: susceptibility and severity risk factors. MSVirtual2020; ECTRIMS\/ACTRIMS; 11\u201313 Sept 2020."},{"key":"804_CR30","unstructured":"Klineova S, Harel A, Straus Farber R, Zhang Y, Deangelis T, Leung TM, et al. COVID-19 infection in patients with multiple sclerosis: an observational study by The New York COVID-19 Neuro-Immunology Consortium (NYCNIC). MSVirtual2020; ECTRIMS\/ACTRIMS; 11-13 Sep 2020."},{"issue":"10","key":"804_CR31","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1177\/1352458520942198","volume":"26","author":"FC Loonstra","year":"2020","unstructured":"Loonstra FC, Hoitsma E, van Kempen ZL, Killestein J, Mostert JP. COVID-19 in multiple sclerosis: the Dutch experience. Mult Scler. 2020;26(10):1256\u201360.","journal-title":"Mult Scler."},{"key":"804_CR32","doi-asserted-by":"publisher","first-page":"117147","DOI":"10.1016\/j.jns.2020.117147","volume":"418","author":"F Chaudhry","year":"2020","unstructured":"Chaudhry F, Bulka H, Rathnam AS, Said OM, Lin J, Lorigan H, et al. COVID-19 in multiple sclerosis patients and risk factors for severe infection. J Neurol Sci. 2020;418:117147.","journal-title":"J Neurol Sci."},{"key":"804_CR33","doi-asserted-by":"publisher","unstructured":"Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, et al. Musc-19 Study Group. Disease modifying therapies and COVID-19 severity in multiple sclerosis. Ann Neurol. 2021. https:\/\/doi.org\/10.1002\/ana.26028.","DOI":"10.1002\/ana.26028"},{"key":"804_CR34","unstructured":"IBM. Explorys EHR solutions. https:\/\/www.ibm.com\/products\/explorys-ehr-data-analysis-tools. Accessed 9 Dec 2020."},{"issue":"6","key":"804_CR35","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1136\/annrheumdis-2020-217566","volume":"79","author":"A Mathian","year":"2020","unstructured":"Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, Amador-Borrero B, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis. 2020;79(6):837\u20139.","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"804_CR36","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1007\/s10067-020-05376-x","volume":"39","author":"S Najafi","year":"2020","unstructured":"Najafi S, Rajaei E, Moallemian R, Nokhostin F. The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach. Clin Rheumatol. 2020;39(11):3223\u201335.","journal-title":"Clin Rheumatol."},{"key":"804_CR37","unstructured":"International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonized tripartite guideline: guideline for good clinical practice. J Postgrad Med. 2001;47(1):45\u201350."},{"key":"804_CR38","unstructured":"Simpson-Yap S, De Brouwer E, Kalincik T, Rijke N, Hillert J, Walton C, et al. First results of the COVID-19 in MS Global Data Sharing Initiative suggest anti-CD20 DMTs are associated with worse COVID-19 outcomes. MSVirtual2020; ECTRIMS\/ACTRIMS; 11\u201313 Sept 2020."},{"key":"804_CR39","unstructured":"Mendes MF, Ferreira MI, Sousa NA, Thomaz R, Ap\u00f3stolos-Pereira SL, Alves-Leon S, et al. Incidence and clinical outcome of COVID-19 in a cohort of 11.560 Brazilian patients with multiple sclerosis. MSVirtual2020; ECTRIMS\/ACTRIMS; 11\u201313 Sept 2020."},{"issue":"4","key":"804_CR40","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrneurol.2016.21","volume":"12","author":"A Winkelmann","year":"2016","unstructured":"Winkelmann A, Loebermann M, Reisinger EC, Hartung HP, Zettl UK. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol. 2016;12(4):217\u201333.","journal-title":"Nat Rev Neurol."},{"issue":"9","key":"804_CR41","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s40263-020-00756-y","volume":"34","author":"C Zheng","year":"2020","unstructured":"Zheng C, Kar I, Chen CK, Sau C, Woodson S, Serra A, et al. Multiple sclerosis disease-modifying therapy and the COVID-19 pandemic: implications on the risk of infection and future vaccination. CNS Drugs. 2020;34(9):879\u201396.","journal-title":"CNS Drugs"},{"key":"804_CR42","doi-asserted-by":"publisher","first-page":"102195","DOI":"10.1016\/j.msard.2020.102195","volume":"43","author":"F Safavi","year":"2020","unstructured":"Safavi F, Nourbakhsh B, Azimi AR. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord. 2020;43:102195.","journal-title":"Mult Scler Relat Disord."},{"key":"804_CR43","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.08.21251316","author":"S Simpson-Yap","year":"2021","unstructured":"Simpson-Yap S, De Brouwer E, Kalincik T, Rijke N, Hillert J, Walton C, et al. Associations of DMT therapies with COVID-19 severity in multiple sclerosis. medRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.02.08.21251316.","journal-title":"medRxiv"},{"issue":"3","key":"804_CR44","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1212\/CPJ.0000000000000238","volume":"6","author":"RJ Fox","year":"2016","unstructured":"Fox RJ, Chan A, Gold R, Phillips JT, Selmaj K, Chang I, et al. Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: patient management considerations. Neurol Clin Pract. 2016;6(3):220\u20139.","journal-title":"Neurol Clin Pract."},{"issue":"13","key":"804_CR45","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1177\/1352458519881761","volume":"26","author":"RT Naismith","year":"2020","unstructured":"Naismith RT, Wolinsky JS, Wundes A, LaGanke C, Arnold DL, Obradovic D, et al. Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Mult Scler. 2020;26(13):1729\u201339.","journal-title":"Mult Scler."},{"key":"804_CR46","doi-asserted-by":"crossref","unstructured":"Longbrake EE, Mao-Draayer Y, Cascione M, Zielinski T, Bame E, Brassat D, et al. Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity. Mult Scler. 2020:1352458520937282.","DOI":"10.1177\/1352458520937282"},{"issue":"1","key":"804_CR47","doi-asserted-by":"publisher","first-page":"e409","DOI":"10.1212\/NXI.0000000000000409","volume":"5","author":"C von Hehn","year":"2018","unstructured":"von Hehn C, Howard J, Liu S, Meka V, Pultz J, Mehta D, et al. Immune response to vaccines is maintained in patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm. 2018;5(1):e409.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"15","key":"804_CR48","doi-asserted-by":"publisher","first-page":"e1724","DOI":"10.1212\/WNL.0000000000007262","volume":"92","author":"D Mehta","year":"2019","unstructured":"Mehta D, Miller C, Arnold DL, Bame E, Bar-Or A, Gold R, et al. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice. Neurology. 2019;92(15):e1724\u201338.","journal-title":"Neurology"},{"key":"804_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09690-6","author":"F Schweitzer","year":"2020","unstructured":"Schweitzer F, Laurent S, Fink GR, Barnett MH, Hartung HP, Warnke C. Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis. J Neurol. 2020. https:\/\/doi.org\/10.1007\/s00415-019-09690-6.","journal-title":"J Neurol."},{"issue":"5","key":"804_CR50","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-018-8812-0","volume":"265","author":"EC Tallantyre","year":"2018","unstructured":"Tallantyre EC, Whittam DH, Jolles S, Paling D, Constantinesecu C, Robertson NP, et al. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. J Neurol. 2018;265(5):1115\u201322.","journal-title":"J Neurol."},{"key":"804_CR51","unstructured":"Reder A, Adamo A, Wicklein E-M, Bhatti A. Use and safety of interferon beta-1b during the COVID-19 outbreak: current data from a pharmacovigilance safety database. MSVirtual2020; ECTRIMS\/ACTRIMS; 11\u201313 Sept 2020."},{"key":"804_CR52","unstructured":"Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4570."},{"key":"804_CR53","doi-asserted-by":"publisher","unstructured":"Pairo-Castineira E, Clohisey S, Klaric L, Bretherick A, Rawlik K, Parkinson N, et al. Genetic mechanisms of critical illness in COVID-19. MedRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.09.24.20200048.","DOI":"10.1101\/2020.09.24.20200048"},{"key":"804_CR54","unstructured":"Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585."},{"issue":"2","key":"804_CR55","doi-asserted-by":"publisher","first-page":"a029249","DOI":"10.1101\/cshperspect.a029249","volume":"9","author":"T Prod'homme","year":"2019","unstructured":"Prod\u2019homme T, Zamvil SS. The evolving mechanisms of action of glatiramer acetate. Cold Spring Harb Perspect Med. 2019;9(2):a029249.","journal-title":"Cold Spring Harb Perspect Med."},{"issue":"10","key":"804_CR56","doi-asserted-by":"publisher","first-page":"e0240305","DOI":"10.1371\/journal.pone.0240305","volume":"15","author":"M Melnikov","year":"2020","unstructured":"Melnikov M, Sharanova S, Sviridova A, Rogovskii V, Murugina N, Nikolaeva A, et al. The influence of glatiramer acetate on Th17-immune response in multiple sclerosis. PLoS ONE. 2020;15(10):e0240305.","journal-title":"PLoS ONE"},{"issue":"3","key":"804_CR57","doi-asserted-by":"publisher","first-page":"e698","DOI":"10.1212\/NXI.0000000000000698","volume":"7","author":"D Hausler","year":"2020","unstructured":"Hausler D, Hajiyeva Z, Traub JW, Zamvil SS, Lalive PH, Bruck W, et al. Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS. Neurol Neuroimmunol Neuroinflamm. 2020;7(3):e698.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"804_CR58","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.3389\/fimmu.2019.01564","volume":"10","author":"PS Rommer","year":"2019","unstructured":"Rommer PS, Milo R, Han MH, Satyanarayan S, Sellner J, Hauer L, et al. Immunological aspects of approved MS therapeutics. Front Immunol. 2019;10:1564.","journal-title":"Front Immunol."},{"issue":"14","key":"804_CR59","doi-asserted-by":"publisher","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","volume":"95","author":"A Bar-Or","year":"2020","unstructured":"Bar-Or A, Calkwood JC, Chognot C, Evershed J, Fox EJ, Herman A, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study. Neurology. 2020;95(14):e1999-2008.","journal-title":"Neurology"},{"issue":"6","key":"804_CR60","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jaci.2011.08.008","volume":"128","author":"MD Pescovitz","year":"2011","unstructured":"Pescovitz MD, Torgerson TR, Ochs HD, Ocheltree E, McGee P, Krause-Steinrauf H, et al. Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol. 2011;128(6):1295-302.e5.","journal-title":"J Allergy Clin Immunol."},{"key":"804_CR61","unstructured":"Genentech. Ocrevus highlights of prescribing information. 2020. https:\/\/www.gene.com\/download\/pdf\/ocrevus_prescribing.pdf. Accessed 19 Jan 2021."},{"key":"804_CR62","doi-asserted-by":"crossref","unstructured":"Mateen FJ, Rezaei S, Alakel N, Gazdag B, Kumar AR, Vogel A. Impact of COVID-19 on U.S. and Canadian neurologists' therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices. J Neurol. 2020;267(12):3467\u201375.","DOI":"10.1007\/s00415-020-10045-9"},{"key":"804_CR63","unstructured":"National Multiple Sclerosis Society. MS treatment guidelines during the coronavirus pandemic. https:\/\/www.nationalmssociety.org\/coronavirus-covid-19-information\/multiple-sclerosis-and-coronavirus\/ms-treatment-guidelines-during-coronavirus. Accessed 8 Feb 2021."},{"key":"804_CR64","unstructured":"MS-UK. MS and COVID-19. 2021. https:\/\/www.ms-uk.org\/ms-and-coronavirus. Accessed 25 Jan 2021."},{"key":"804_CR65","doi-asserted-by":"publisher","first-page":"102192","DOI":"10.1016\/j.msard.2020.102192","volume":"42","author":"R Hughes","year":"2020","unstructured":"Hughes R, Pedotti R, Koendgen H. COVID-19 in persons with multiple sclerosis treated with ocrelizumab \u2013 a pharmacovigilance case series. Mult Scler Relat Disord. 2020;42:102192.","journal-title":"Mult Scler Relat Disord."},{"key":"804_CR66","doi-asserted-by":"publisher","DOI":"10.1007\/s42399-020-00504-9","author":"S Sadeghmousavi","year":"2020","unstructured":"Sadeghmousavi S, Rezaei N. COVID-19 and multiple sclerosis: predisposition and precautions in treatment. SN Compr Clin Med. 2020. https:\/\/doi.org\/10.1007\/s42399-020-00504-9.","journal-title":"SN Compr Clin Med."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00804-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-021-00804-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00804-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,28]],"date-time":"2021-03-28T09:13:01Z","timestamp":1616922781000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-021-00804-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["804"],"URL":"https:\/\/doi.org\/10.1007\/s40263-021-00804-1","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"10 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Biogen providing funding for the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Anthony T. Reder has received unrestricted research support from Bayer, Biogen, Roche-Genentech, Mallinckrodt, Merck-Serono, and Novartis, and is a consultant for Bayer, Biogen, NKMax America, Merck-Serono, Novartis, and Roche-Genentech. Diego Centonze is an advisory board member of Almirall, Celgene, BMS, Bayer Schering, Biogen, GW Pharmaceuticals, Merck Serono, Novartis, Roche, Sanofi-Genzyme, and Teva and has received honoraria for speaking or consultation fees from Almirall, Bayer Schering, Biogen, GW Pharmaceuticals, Merck Serono, Novartis, Roche, Sanofi-Genzyme, and Teva. He is also the principal investigator in clinical trials for Abbvie, Zambon, Bayer Schering, Biogen, Merck Serono, Mitsubishi, Novartis, Roche, Sanofi-Genzyme, and Teva. His preclinical and clinical research was supported by grants from Bayer Schering, Biogen, Celgene, Lundbeck, Merck Serono, Novartis, Roche, Sanofi-Genzyme, and Teva. Maria L. Naylor, Anjali Nagpal, Rajani Rajbhandari, Arman Altincatal, Michelle Kim, Aaron Berdofe, Maha Radhakrishnan, Eunice Jung, Alfred W. Sandrock, Karen Smirnakis, Catrinel Popescu, and Carl de Moor are employees and hold stock\/stock options in Biogen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The data extracted from the databases were entirely anonymized and therefore do not require informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated during and\/or analyzed during the current study are not publicly available because Biogen does not own the data and it would be difficult to make this data source public, but the portions that are publicly available will be provided by the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors have read and approved the final manuscript. ATR provided writing, data analysis, and the scientific basis of the text. DC provided discussion on methods of the study and critical reading of the manuscript. MLN and AN provided the scientific basis of the text, data analysis and interpretation, and writing. RR and AA provided data analysis and interpretation. MK and AB provided data management and informatics support. MR provided the scientific basis of the text and interpretation. EJ provided electronic health record subject matter expert guidance, and data management and informatics support. AWS provided the scientific basis of the text and interpretation. KS and CP provided expert information from the Biogen Global Safety Database. CdM provided data analysis and interpretation.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}